Status:
RECRUITING
Evaluation of Obicetrapib on Antioxidant Levels in Plasma and HDL Particles of Healthy Volunteers
Lead Sponsor:
NewAmsterdam Pharma
Collaborating Sponsors:
MB Clinical Research and Consulting LLC
Conditions:
Antioxidant Absorption
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
The goal of this clinical trial is to learn if Obicetrapib works to change antioxidant levels in HDL and plasma, as well as retinal tissue. The main questions it aims to answer are: Do Obicetrapib ef...
Eligibility Criteria
Inclusion
- Visual acuity \> 20/60 in both eyes with or without corrective lenses
Exclusion
- Type 2 diabetes
- Active liver disease
- Any clinically significant macular pathology
Key Trial Info
Start Date :
September 9 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2026
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT06982508
Start Date
September 9 2025
End Date
December 1 2026
Last Update
October 17 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Excellence Medical Research
Miami Gardens, Florida, United States, 33169